June 06, 2022
Article
“ENZAMET adds to the body of knowledge from several other pivotal trials and now informs best practices for mHSPC,” said Ian D. Davis, MBBS, PhD, FRACP, FAChPM.
May 24, 2022
Article
Patients in the study had tumors that were not completely resectable.
May 17, 2022
Article
The neoadjuvant combination of the PD-1 inhibitor tislelizumab and nab-paclitaxel induced a high rate of pathologic complete response in patients with muscle-invasive bladder cancer.
February 20, 2022
Article
The final overall survival analysis from the phase 3 CheckMate 9ER trial continued to show a benefit with frontline nivolumab/cabozantinib versus sunitinib in patients with advanced renal cell carcinoma.